US 2020/0190480 A1Published application

ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING

AssigneeNext Pharma Inc.

InventorsMahmood MOSHIRI, Kiarash MOSHIRI, Arsha MOSHIRI, Mohammad Hadi SEKHAVATI, Hassan MONHEMI

Life of this patent

Estimating the term…

Loading patent…

Abstract

Provided herein are polypeptide epitopes of aspartyl-(asparaginyl)-3-hydroxylase (“AABH”) as well as polyepitopes thereof. Also provided are antibodies that specifically bind these polypeptide epitopes and poly epitopes, as well as binding the aspartyl-(asparaginyl)-3-hydroxylase protein itself. The disclosure further provides methods of assaying for AABH polypeptide epitopes, cells expressing these polypeptide epitopes and the AABH protein. Also provided are methods of diagnosing cancer by the detection of AABH peptides and methods of treating cancer by targeting cells that express AABH.

A method of making a hybridoma that produces antibodies against aspartyl (asparaginyl) β-hydroxylase (“AABH”) comprising:

a) immunizing an animal with a polypeptide to elicit an immune response, wherein the polypeptide is selected from:
(i) a polypeptide having an amino acid sequence consisting of, or consisting essentially of:
SEQ ID NO:
1
CRRGQIKYS;
SEQ ID NO:
2
GPTNCRLRMHLGLVI;
SEQ ID NO:
3
RT WEEGKVLIFD;
SEQ ID NO:
4
WQD ASSFRLIFI;
SEQ ID NO:
5
LS GTSFFTWFMVIALLGVWTSV;
SEQ ID NO:
6
VYEEVLSVTPNDGFAKVHYGFILKAQNK;
SEQ ID NO:
7
FASVWQRSLYNVNGLK;
SEQ ID NO:
8
GLSGTSFFTWFMVIALLGVWTSVA;
SEQ ID NO:
9
GDGDFDVDDAKVLLGLKERSTSEPAV;
SEQ ID NO:
10
IEEAVNAFKELVRKYPQSPRARYGKAQC;
SEQ ID NO:
11
DVPADLLKLSLKRRSDRQQFLGH;
SEQ ID NO:
12
SLERNWKLIRDEGLAVMDKAKGL;
SEQ ID NO:
13
GFAKVHYGFILKAQNKIAESIP;
SEQ ID NO:
14
HTGPTNCRLRMHLGLVIPKEGC;
SEQ ID NO:
15
DSFEHEVWQDASSFRLIFIVDVW;
SEQ ID NO:
16
MRGSLLTLQRLVQLFPNDTSLKN;
SEQ ID NO:
17
PQQEDDEFLMATDVDDRFETL;
SEQ ID NO:
18
DGRFYFHLGDAMQRVGNKEAY;
SEQ ID NO:
19
GLSGTSFFTWFMVIALLGVWTSVAGGSGGGFAKVHYGFILKAQNKIAESI
P;
SEQ ID NO:
20
KVYEEVLSVE EVLSVTPNTP NDGFAKVGFA KVHYGFKVHY
GFILKKIAES IPYL;
SEQ ID NO:
21
GTDDGRFYFRVGNKEAYKASVWQRSLYSLYNVNGLK;
SEQ ID NO:
22
SFFTWFMVIALLGVWTSVA;
SEQ ID NO:
23
PADLLKLSLKRRSDRQQF;
SEQ ID NO:
24
GFAKVHYGFILKAQNKIAESIPY;
SEQ ID NO:
25
TGPTNCRLRMHLGLVIPKEGC;
SEQ ID NO:
26
FEHEVWQDASSFRLIFVDVWHPEL;
SEQ ID NO:
27
EHVEGEDLQQEDGPTGEPQQEDDEFL;
SEQ ID NO:
28
PYLKEGIESGDPGTDDGR;
SEQ ID NO:
29
GLKAQPWWTPKETGYTE;
SEQ ID NO:
30
LKAQNKIAESIPYLKEGI;
SEQ ID NO:
31
HLGDAMQRVGNKEAYKWYELGHKRGHFASVW;
SEQ ID NO:
32
VDVWHPELTPQQRRSLPAI;
SEQ ID NO:
33
KNAKSSGNSSSSGSGSGSTSAGSSSPGARRE;
SEQ ID NO:
34
IYDADGDGDFDVDDAKVLLGLKERSTSEPAVP;
SEQ ID NO:
35
EEMM SEQENPDSSEPVVE;
or
SEQ ID NO:
36
FPVEEQQEVPPETNRKTDDPEQKAKVKKKK.
(ii) a polypeptide having an amino acid sequence consisting of a fragment of a polypeptide selected from SEQ ID NO:
1-SEQ ID NO:
36, wherein the fragment is no more than 1, 2, 3 or 4 amino acids shorter than the polypeptide selected from SEQ ID NO:
1-SEQ ID NO:
36;
(iii) a chimeric polyepitope comprising 2, 3 or 4 polypeptides having an amino acid sequence consisting of, or consisting essentially of a polypeptide selected from SEQ ID NO:
1-SEQ ID NO:
36, wherein the polypeptides are covalently connected through one or more linkers;
and
(iv) a polypeptide having an amino acid sequence consisting of, or consisting essentially of SEQ ID NO:
38—AABH Fragment 1 or SEQ ID NO:
39—AABH Fragment 2;
b) isolating B cells from the animal;
c) fusing the isolated B cells with HAT-sensitive myeloma cells to produce hybridoma cells;
and
d) selecting HAT (hypoxanthine-aminopterin-thymidine) tolerant hybridoma cells that produce antibodies that bind to the polypeptide.

126 more elements

Facts

Application

16/643,509Filed 28 Aug 2018

Priority

30 Aug 2017

Published

18 Jun 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

A61P 35/00
Antineoplastic agents
C12N 5/163
Animal cells: one of the fusion partners being a B or a T lymphocyte
A61K 38/44
Enzymes; Proenzymes; Derivatives thereof: oxidoreductases
A61K 39/0011
Vertebrate antigens: cancer antigens

Abstract

Claims83